Share Email Print
cover

Journal of Biomedical Optics

Anticancer phototherapy using activation of E-combretastatins by two-photon–induced isomerization
Author(s): Kathrin M. Scherer; Roger H. Bisby; Stanley W. Botchway; John A. Hadfield; Anthony W. Parker
Format Member Price Non-Member Price
PDF $20.00 $25.00

Paper Abstract

The photoisomerization of relatively nontoxic E-combretastatins to clinically active Z-isomers is shown to occur in solution through both one- and two-photon excitations at 340 and 625 nm, respectively. The photoisomerization is also demonstrated to induce mammalian cell death by a two-photon absorption process at 625 nm. Unlike conventional photodynamic therapy (PDT), the mechanism of photoisomerization is oxygen-independent and active in hypoxic environments such as in tumors. The use of red or near-infrared (NIR) light for two-photon excitation allows greater tissue penetration than conventional UV one-photon excitation. The results provide a baseline for the development of a novel phototherapy that overcomes nondiscriminative systemic toxicity of Z-combretastatins and the limitations of PDT drugs that require the presence of oxygen to promote their activity, with the added benefits of two-photon red or NIR excitation for deeper tissue penetration.

Paper Details

Date Published: 27 October 2014
PDF: 6 pages
J. Biomed. Opt. 20(5) 051004 doi: 10.1117/1.JBO.20.5.051004
Published in: Journal of Biomedical Optics Volume 20, Issue 5
Show Author Affiliations
Kathrin M. Scherer, STFC Rutherford Appleton Lab. (United Kingdom)
Univ. of Salford (United Kingdom)
Roger H. Bisby, Univ. of Salford (United Kingdom)
Stanley W. Botchway, STFC Rutherford Appleton Lab. (United Kingdom)
John A. Hadfield, Univ. of Salford (United Kingdom)
Anthony W. Parker, STFC Rutherford Appleton Lab. (United Kingdom)


© SPIE. Terms of Use
Back to Top